These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 8267416)

  • 1. IGIV prophylaxis therapy for CMV in renal transplant recipients.
    Mendoza M
    ANNA J; 1993 Dec; 20(6):691-2. PubMed ID: 8267416
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytomegalovirus prophylaxis with intravenous polyvalent immunoglobulin in high-risk renal transplant recipients.
    Leroy F; Sechet A; Abou Ayache R; Thierry A; Belmouaz S; Desport E; Bauwens M; Bridoux F; Touchard G
    Transplant Proc; 2006 Sep; 38(7):2324-6. PubMed ID: 16980080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMV-enriched immune globulin produces consistent reliable results in renal transplant patients.
    Finn WF
    Transplantation; 1993 Aug; 56(2):491. PubMed ID: 7689267
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevention of cytomegalovirus infection and disease in high-risk renal transplant recipients with polyvalent intravenous immunoglobulins.
    Séchet A; Bridoux F; Bauwens M; Ayache RA; Belmouaz S; Touchard G
    Transplant Proc; 2002 May; 34(3):812-3. PubMed ID: 12034192
    [No Abstract]   [Full Text] [Related]  

  • 5. The use of intravenous immune globulin in organ transplantation.
    Platt D; Maderazo E; Chime-Udeh E
    Conn Med; 1991 Aug; 55(8):468-70. PubMed ID: 1657517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of cytomegalovirus disease in transplant recipients.
    Pidgeon GB; Bailey RR
    N Z Med J; 1993 Nov; 106(967):468-9. PubMed ID: 8233192
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of cytomegalovirus prophylaxis in renal retransplantation.
    Singh TP; Gruber SA; Lempert N; Freed B; Conti DJ
    Transplant Proc; 1995 Feb; 27(1):964-5. PubMed ID: 7879247
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients--a meta-analysis.
    Glowacki LS; Smaill FM
    Clin Transplant; 1994 Feb; 8(1):10-8. PubMed ID: 8136560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose valaciclovir and cytomegalovirus immunoglobulin to prevent cytomegalovirus disease in high-risk renal transplant recipients.
    Toussaint ND; Tan MB; Nicholls K; Walker RG; Cohney SJ
    Nephrology (Carlton); 2011 Jan; 16(1):113-7. PubMed ID: 21175987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients.
    Snydman DR; Werner BG; Heinze-Lacey B; Berardi VP; Tilney NL; Kirkman RL; Milford EL; Cho SI; Bush HL; Levey AS
    N Engl J Med; 1987 Oct; 317(17):1049-54. PubMed ID: 2821397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic immunoglobulin therapy improves the outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease.
    Conti DJ; Freed BM; Lempert N
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1421-2. PubMed ID: 8382867
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient.
    Uber L; Cofer J; Baliga P; Rajagopalan PR
    Transplant Proc; 1995 Oct; 27(5 Suppl 1):42-3. PubMed ID: 7482818
    [No Abstract]   [Full Text] [Related]  

  • 13. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
    Fricke L; Steinhoff J; Hartwig-Weber I; Bein G
    Dtsch Med Wochenschr; 1997 May; 122(18):565-71. PubMed ID: 9190308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiviral prophylaxis and pre-emptive therapy for the prevention of Cytomegalovirus infection in renal transplant recipients: guideline from the Italian Society of Nephrology].
    Cornella C; Torazza MC; Strippoli GF; Segoloni G;
    G Ital Nefrol; 2007; 24 Suppl 37():S165-78. PubMed ID: 17347963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The problem of cytomegalovirus (CMV) prophylaxis in high-risk renal transplant recipients.
    Maiwald J; Sperschneider H; Stein G
    Nephrol Dial Transplant; 1996 Sep; 11(9):1897. PubMed ID: 8918658
    [No Abstract]   [Full Text] [Related]  

  • 16. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
    Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
    Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of cytomegalovirus immune globulin.
    Snydman DR
    Clin Pharm; 1992 Aug; 11(8):674-5. PubMed ID: 1324822
    [No Abstract]   [Full Text] [Related]  

  • 18. [CMV and kidney transplant: prophylaxis and therapy].
    Sgarabotto D; Marinello S
    G Ital Nefrol; 2012; 29 Suppl 56():S94-8. PubMed ID: 23059946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
    J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients.
    López-Medrano F; Rueda B; Lizasoain M; Juan RS; Folgueira D; Andrés A; Morales JM; Jiménez C; Meneu JC; Aguado JM
    Transpl Infect Dis; 2009 Oct; 11(5):400-4. PubMed ID: 19570139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.